1. Home
  2. TGHL vs BCDA Comparison

TGHL vs BCDA Comparison

Compare TGHL & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.42

Market Cap

13.9M

Sector

Technology

ML Signal

N/A

Logo BioCardia Inc.

BCDA

BioCardia Inc.

N/A

Current Price

$0.87

Market Cap

15.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGHL
BCDA
Founded
2020
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
15.7M
IPO Year
2024
2009

Fundamental Metrics

Financial Performance
Metric
TGHL
BCDA
Price
$0.42
$0.87
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
73.5K
★ 119.8K
Earning Date
05-15-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.27
$0.75
52 Week High
$2.48
$1.80

Technical Indicators

Market Signals
Indicator
TGHL
BCDA
Relative Strength Index (RSI) 27.15 39.38
Support Level $0.33 $0.82
Resistance Level $0.50 $1.28
Average True Range (ATR) 0.08 0.08
MACD -0.01 -0.00
Stochastic Oscillator 0.28 11.01

Price Performance

Historical Comparison
TGHL
BCDA

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: